Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

16. december 2014 opdateret af: Bukwang Pharmaceutical
This is a open, randomized, parallel study. Subjects will have Clevudine or Entecavir therapy for 48 weeks(Clevudine:Entecavir = 2:1), and subjects who have Complete Response(HBV DNA negative and ALT normal) will have follow-up period for additional 48 weeks.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

75

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patient who is older than 18.
  2. Patient who is HBsAg positive for the previous 6 months and with HBV DNA ≥ 1 x 10^5 copies/mL
  3. Patient who is HBeAg negative.
  4. Patient with ALT≥1×ULN.
  5. Patient who is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria:

  1. Patient is currently receiving antiviral, immunomodulatory, cytotoxic or corticosteroid therapy.
  2. Patient is treated with interferon for the previous 6 months.
  3. Patient has been treated previously with clevudine, lamivudine, adefovir, entecavir, telbivudine or any other investigational nucleoside for HBV infection.
  4. Patient is coinfected with HCV, HDV or HIV.
  5. Patient has evidence of ascites, variceal hemorrhage and/or hepatic encephalopathy.
  6. Patient has evidence of decompensated Liver cirrhosis and/or hepatocellular carcinoma.
  7. Patient has a history of organ transplantation.
  8. Patient has the treatment of nephrotoxicity drugs, competitive drugs for kidney to excrete, and/or hepatotoxicity drugs for the previous 2 months from screening.
  9. Patient is pregnant or breast-feeding.
  10. Patient has a clinically relevant history of abuse of alcohol or drugs.
  11. Patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone, neurological, cardiac, oncologic, allergic disease or medical illness that in the investigator's opinion might interfere with therapy. The patient with a benign tumor, excluded if judged by an investigator that the continuation of study would be interfered by the tumor.
  12. Patient has creatinine clearance less than 60mL/min as estimated by the following formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 1
Clevudine 30mg
Medicin: Clevudine
30 mg, QD
Andre navne:
  • Levovir
Aktiv komparator: 2
Entecavir 0.5mg
Medicin: Entecavir
0.5mg QD
Andre navne:
  • Baraclude

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Intrahepatic cccDNA reduction from baseline
Tidsramme: week 48
week 48

Sekundære resultatmål

Resultatmål
Tidsramme
Proportion of patients with HBV DNA below LOD by real-time PCR
Tidsramme: day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
Reduction of HBV DNA level from baseline
Tidsramme: day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
ALT normalization
Tidsramme: day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
Reduction of sAg titer from baseline
Tidsramme: day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
day1(predose), every 12 weeks during treatment period(48weeks), every 8 weeks during follow-up period(48weeks)
Proportion of maintaining sustained effect
Tidsramme: every 8 weeks during follow-up period(48weeks)
every 8 weeks during follow-up period(48weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Bukwang Pharmaceutical

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. august 2009

Primær færdiggørelse (Faktiske)

1. august 2013

Studieafslutning (Faktiske)

1. januar 2014

Datoer for studieregistrering

Først indsendt

19. december 2010

Først indsendt, der opfyldte QC-kriterier

22. december 2010

Først opslået (Skøn)

24. december 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

18. december 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. december 2014

Sidst verificeret

1. december 2014

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • CLV-410

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Kronisk hepatitis B

Kliniske forsøg med Clevudine

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Portugal

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner